YIKEDA™ accélère son expansion internationale lors du salon ASIA FRUIT LOGISTICA 2026 : Renforcement des partenariats, lancement de tomates cerises exclusives dotées d'un label de traçabilité

HONG KONG et SHANGHAI, 9 septembre 2026 /PRNewswire/ -- Du 2 au 4 septembre 2026, ASIA FRUIT LOGISTICA 2026, le salon professionnel international de référence et le plus influent du secteur des fruits et légumes frais en Asie, s'est tenu à l'AsiaWorld-Expo de Hong Kong, en Chine. YIKEDA™, une marque haut de gamme de tomates, a fait un retour triomphal avec l'ensemble de sa gamme, en lançant ses tomates cerises dotées d'un label de traçabilité exclusif.

Lors du salon de cette année, l'expansion internationale de YIKEDA™ s'est imposée comme l'un des principaux centres d'intérêt. Des acheteurs venus de divers pays se sont pressés au stand de YIKEDA™ afin d'envisager des collaborations. Il convient notamment de noter que YIKEDA™ a présenté pour la première fois ses tomates cerises dotées d'un système exclusif de traçabilité lors d'un salon international, apaisant ainsi les inquiétudes des consommateurs en matière de sécurité alimentaire grâce à une gestion visible de la qualité.

À l'heure actuelle, les produits YIKEDA™ ont été successivement commercialisés dans les RAS de Hong Kong et de Macao, et ont été exportés vers des pays tels que les États-Unis, le Canada, la Russie, la Thaïlande, le Vietnam, le Cambodge et le Laos.

La reconnaissance internationale croissante dont bénéficient les tomates cerises phares de YIKEDA™ repose sur son contrôle qualité couvrant l'ensemble de la chaîne de production, de la graine à l'assiette. Fondée en 2022, la société YIKEDA™ est une filiale de Qingdao Triumph Haofeng Smart Agriculture Technology Co., Ltd. (ci-après dénommée « Triumph Haofeng »), le plus grand exploitant et prestataire de services de serres intelligentes en verre de Chine. En se concentrant sur la catégorie des tomates de table, cultivées dans 267 hectares de serres en verre « intelligentes » construites et exploitées par Triumph Haofeng en Chine, la marque a mis en place un système de contrôle numérisé et standardisé tout au long de la chaîne de production, de la « graine » à la « table », garantissant ainsi un approvisionnement stable tout au long de l'année.

Les tomates cerises YIKEDA™ sont exemptes d'hormones artificielles et de métaux lourds ; elles offrent une saveur intense et une texture croquante, et ont obtenu la première certification alimentaire « faible indice glycémique » du secteur de la tomate en Chine. Les tomates cerises YIKEDA™ et le jus de tomate 100 % pur jus (NFC) ont été désignés par le cabinet d'expertise Frost & Sullivan comme les produits les plus vendus en Chine pendant deux années consécutives.

YIKEDA™ a présenté l'ensemble de sa gamme de produits lors du salon AFL 2026, notamment du jus de tomate 100 % NFC et des boissons aromatisées à la tomate. La formulation clean label du jus de tomate 100 % NFC — qui ne contient « que des tomates pures, sans ajout d'eau » — a également été très appréciée par de nombreux clients internationaux.

À l'avenir, YIKEDA™ continuera à se consacrer pleinement au secteur de la tomate de table, en stimulant le développement de produits et l'expansion de ses réseaux de distribution avec une vision mondiale, afin de faire de YIKEDA™ une marque de tomates de table de classe mondiale au service de l'ensemble de la planète.

Contact : 

Ria 

WhatsApp : +86 15353599276

E-mail : [email protected]

Share this article

New Behavior Insights show pet parents the DNA behind the barking, the lunging and the 2 a.m. zoomies and pair it with a year of guided training built around their dog

BOSTON, Sept. 9, 2026 /PRNewswire/ -- Today, Embark Veterinary Inc., the global leader in dog health and genetics, launched Behavior Insights & Training, a new feature that translates a dog's DNA into 15 genetic behavior insights and pairs them with one year of personalized, guided training.

Behavior Insights is built on the idea that a dog's quirks aren't random and can often be traced to genetic tendencies that shape how a dog reacts to the world. The new feature gives pet parents a glimpse into who their dog is and why they may be wary of new visitors, anxious when the keys jingle, or uncomfortable around other dogs. Rather than leaving pet parents to guess at generic breed advice, Embark shows why a dog may be predisposed to those behaviors, and pairs that insight with training guidance shaped around the dog you already love, quirks and all.

"Every dog owner knows the feeling of loving a dog whose habits don't fully make sense to them," said Amish Desai, Embark CEO. "Behavior Insights gives pet parents a genetic starting point for understanding those habits, so training feels less like guesswork and more like working with their dog's wiring instead of against it."

Behavior Insights, an in-app upgrade for Breed ID and Breed + Health customers, delivers 15 insights connecting a dog's genetics to predispositions like hyperactivity, separation anxiety, anxiety around unfamiliar objects or other dogs, and a tendency to feel easily overwhelmed. Alongside the insights, customers receive a year of guided training through a personalized plan rooted in their dog's behavior insights, created in partnership with Dogo. The program, accessible through the Embark app, is already used by more than 12 million dog parents, and more than 8 in 10 have seen behavior improvements within two weeks.

Behavior Insights are available as a $39 upgrade through the Embark app, and comes with a full year of Dogo at no cost. For more information, visit embarkvet.com/behaviors.

About Embark 

Embark Veterinary, Inc. was launched in 2015 by brothers Adam and Ryan Boyko, who share a passion for scientific research and a lifelong love for dogs. Starting with its best-in-class canine DNA test, Embark has built a platform for scientific discovery that helps accelerate advancements in personalized dog care. Embark offers dog DNA tests that help dog owners, breeders, and veterinarians learn about their dog's breed, health, and ancestry, and its tests fuel ongoing research to help dogs lead longer, healthier lives. Embark is an official research partner of Cornell University College of Veterinary Medicine. For more information, visit www.embarkvet.com, and follow on Instagram, Facebook, TikTok, LinkedIn, and YouTube,

Media Contact:

LaRue PR

[email protected] 

SOURCE Embark Veterinary, Inc.

Share this article

Jamie LaGuardia-Frie Joins BRG as Managing Director in Healthcare Practice

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- BRG today announced that Jamie LaGuardia-Frie has joined the firm as a managing director in its Healthcare practice. Based in New York, she will lead business development and client strategy for the Healthcare Advisory team and work with colleagues across the practice to strengthen client relationships and drive forward the team's market position.

LaGuardia-Frie brings more than 20 years of healthcare experience spanning consulting, growth strategy, client relationship management and healthcare technology. As a trusted advisor to healthcare executives, she has helped organizations identify new opportunities, improve performance and manage risk in a progressively complex healthcare environment.

"Jamie brings expertise and a strong track record of building relationships and identifying strategic opportunities," said Rich Bajner, a managing director and leader of BRG Healthcare Advisory. "Her experience working with healthcare leaders and teams across the industry will be a valuable addition as we continue to expand our Healthcare Advisory capabilities and help clients navigate an increasingly complex market."

LaGuardia-Frie previously served as managing director and chief commercial officer for Alvarez & Marsal's Health Industry Group. She also spent nearly a decade at Guidehouse, including as Health Growth Leader and East Regional Market Leader for Commercial Healthcare. Earlier in her career, she held healthcare consulting, business development and technology roles at Accretive Health and Allscripts.

"I'm excited to join the talented BRG Healthcare Advisory team and contribute to its continued growth," said LaGuardia-Frie. "I look forward to drawing on BRG's global platform and industry expertise to help clients navigate complexity, identify opportunities and achieve strategic priorities."

LaGuardia-Frie earned an MA in communications with a focus on corporate communications from Eastern Illinois University and a BA in communications and journalism from New York Institute of Technology. She also completed the Essential Management Skills for Emerging Leaders program at Harvard Extension School.

About BRG

BRG combines world-leading academic credentials with world-tested business expertise and purpose-built emerging technologies. Our culture centers on agility and connectivity that set us apart and get you ahead.

At BRG, our professionals include specialist consultants, industry experts, renowned academics and leading-edge data scientists. Together, they bring a diversity of real-world experience, data and human and artificial intelligence to economics, disputes and investigations; corporate finance; and performance improvement services that address the most complex challenges facing organizations across the globe.

Our unique structure nurtures the interdisciplinary relationships that give us the edge, laying the groundwork for more informed insights and more original, incisive thinking. When paired with our global reach and resources, our diverse perspectives and technical capabilities make us uniquely capable to address our clients' challenges.

Visit thinkbrg.com to learn more.

SOURCE BRG

Share this article

Partnering with Fitness Trainer Makena Rae to Inspire Guests to Move at Their Own Pace

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Loews Hotels & Co is excited to announce the launch of Active Stays by Loews Hotels, new, on-property fitness offerings created in partnership with fitness trainer Makena Rae to make movement approachable, flexible, and personal for every traveler. Launching across the portfolio just in time for Self-Care Awareness Month, the initiative transforms Loews Hotels into a welcoming home base for well-being, giving guests easy ways to stay active throughout their stay, whether they have ten minutes between meetings or an entire morning to explore a destination on foot.

Unlike traditional hotel fitness programs that emphasize performance or training goals, Active Stays by Loews Hotels is built on the belief that movement should fit the guest, not the other way around. From business travelers looking to reset after a flight to families seeking an activity they can enjoy together, the offerings encourage every guest to move in whatever way feels most natural, at their own pace and without expectations.

At Loews Hotels, we've always believed hospitality is about enriching lives and creating moments of joy," said Kristie Goshow, Chief Commercial Officer, Loews Hotels & Co. "Active Stays by Loews Hotels was created around a simple idea: movement, play, and wellness help us become happier, healthier versions of ourselves. Through our partnership with Makena Rae, we've developed experiences that inspire guests to embrace wellness in ways that feel achievable, enjoyable, and uniquely personal. Whether someone is starting a new wellness journey, staying consistent with an established routine, exploring a destination through movement, or simply taking time to reconnect with themselves through yoga, Active Stays makes it easier to feel good while away from home."

Peloton's survey in March 2026 of 3,000+ active travelers shows that guests increasingly expect hotels to support their full wellness routine, including fitness, sleep quality, stress reduction, and healthier F&B options. With 60% of travelers valuing fitness amenities as much or more than other hotel perks, wellness is no longer a premium add-on but a core driver of hotel choice and guest satisfaction, and underscores the growing guest demand Active Stays is designed to meet.

Active Stays by Loews Hotels also marks the next chapter in the brand's broader commitment to guest well-being, building on the momentum of past initiatives to continue offering guests meaningful, personal ways to feel their best while traveling.

The programming brings well-being to life through two core pillars: accessible movement experiences designed for every guest, paired with recovery and restoration moments that encourage balance throughout each stay.

Fitness That Comes to You with Makena Rae

Recognizing that not every traveler wants or has the time to visit the fitness center, Active Stays introduces a new in-room fitness experience featuring a curated library of equipment-free workouts accessible through guest room TVs. Developed in collaboration with fitness expert Makena Rae, the digital series features short, approachable workouts including targeted workout sessions, mobility exercises, bodyweight strength, and recovery sessions designed specifically for hotel rooms.

Whether preparing for a busy day of meetings or winding down after travel, guests can move whenever it best fits their schedule.

Movement, Your Way

Properties will offer a variety of movement experiences that reflect the unique character of each destination. Examples include;

- Loews Regency New York Hotel is offering a Run. Rest. Regency Marathon Package: including a $50 daily food and beverage credit per room, a curated Central Park running map, a themed amenity, and late check-out. Marathon runners can carbo-load with a special menu at The Regency Bar & Grill and recover with exclusive perks at nearby Ancient Aire Bath. The lobby will also feature a cart stocked with runner essentials all weekend. As a bonus, guests take home complimentary branded pickleball paddles and balls, so they can continue running the courts year-round.

- This October, Live! by Loews – Arlington and Loews Arlington Hotel will partner with the City of Arlington's Walktober initiative, bringing guests and the local community together through movement. As sponsors, both properties are committed to supporting initiatives that promote a healthy and vibrant Arlington community. Guests and locals can pick up curated walking maps to get in their steps around world-class sports and entertainment venues, through the city's museums, or around Mark Holtz Lake in Richard Greene Linear Park.

- Loews Chicago Hotel invites guests to Move Along Route 66 with a curated walking and jogging map that turns a stay into a self-guided tour of the city's most iconic sights. The route begins right at the hotel and heads to Navy Pier, where guests can take in Chicago's lakefront and the official starting point of Route 66, before continuing to additional Mother Road–inspired stops and landmarks throughout the city.

- Loews Atlanta Hotel invites guests to move, train, and recover without ever leaving Midtown, thanks to the newly renovated exhale® Atlanta, now expanded through an integrated partnership with Salt Fitness. Guests can drop into Modern Pilates by Salt for a total-body reformer workout, join a coach-led Train by Salt strength and conditioning session, or unwind in the Recover by Salt studio with contrast therapy, red light therapy, and compression treatments.

Move Well. Recover Well.

Active Stays extends beyond movement to embrace recovery as an essential part of every routine. Properties will introduce refreshed food and beverage offerings centered on hydration and protein-forward choices designed to fuel movement and support recovery. Guests can also indulge in convenient grab-and-go snacks and fresh, seasonal menu items available through restaurants, lounges, and in-room dining. Together, these offerings make it easier for guests to maintain healthy routines while traveling, helping them stay energized, recover well, and feel their best throughout their stay.

As fitness travel continues to evolve far beyond race weekends, today's travelers increasingly seek flexible ways to maintain healthy routines while away from home. Active Stays by Loews Hotels reflects that shift, offering an inclusive approach that serves business travelers, families, and leisure guests seeking moments of movement and restoration during their stay.

Active Stays by Loews Hotels will be available at all properties nationwide beginning September 9. For more information about Loews Hotels & Co or to book your upcoming travel, visit Loews Hotels.

About Loews Hotels & Co

Headquartered in New York City, Loews Hotels & Co is rooted in a rich heritage and excellence in service. The hospitality company encompasses branded independent Loews Hotels and a strong mix of partner-brand hotels. Loews Hotels & Co owns and/or operates 27 hotels and resorts across the U.S., including 11 hotels at Universal Orlando Resort, as part of its partnership with Comcast NBC Universal. Located in major city centers and resort destinations from coast to coast, the Loews Hotels portfolio features properties grounded in family heritage and dedicated to delivering unscripted guest moments with a handcrafted approach. For reservations or more information about Loews Hotels, visit: www.loewshotels.com call 1-800-23-LOEWS.

Media Contact:

[email protected] 

SOURCE Loews Hotels & Co

Share this article

GALWAY, Ireland and BRAINTREE, Mass., Sept. 9, 2026 /PRNewswire/ -- Neurent Medical, the pioneer behind the NEUROMARK® System for the treatment of chronic rhinitis, today announced that it has secured a €25 million growth debt financing facility from Claret Capital Partners.

The financing will support the continued commercial expansion of NEUROMARK®, accelerate investment in sales and marketing initiatives, strengthen the company's balance sheet, and provide additional capital to support future growth opportunities.

The financing follows Neurent Medical's successful €62.5 million Series C financing completed earlier this year, further reinforcing the company's position as a leader in minimally invasive treatments for chronic inflammatory sinonasal diseases.

Brian Shields, CEO of Neurent Medical said:

"This financing represents another important milestone for Neurent Medical as we continue to scale our commercial operations and expand patient access to NEUROMARK. We are delighted to deepen our relationship with Claret Capital Partners, whose continued support reflects confidence in our technology, clinical evidence, commercial progress and long-term vision. The facility provides significant financial flexibility while allowing us to continue executing our growth strategy with minimal dilution to shareholders."

Daniel Mallon, Principal at Claret Capital Partners comments:

"Neurent Medical has demonstrated exceptional progress in establishing NEUROMARK as a leading treatment option for chronic rhinitis. We are pleased to further support the company as it continues its commercial expansion and works to improve outcomes for millions of patients suffering from chronic rhinitis."

About Neurent Medical

Neurent Medical is dedicated to transforming the treatment landscape for chronic inflammatory sinonasal diseases. Its flagship NEUROMARK® System utilizes proprietary impedance-controlled radiofrequency technology to target hyperactive posterior nasal nerves, offering durable relief from chronic rhinitis symptoms. The company is headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts.

For more information visit www.neurentmedical.com.

About Claret Capital Partners

Claret Capital Partners is Europe's largest independent growth debt fund manager. Since 2013, the firm has invested over €1.5bn through its funds, supporting more than 210 companies across the technology, life sciences and impact sectors. Its team has been active in investing into European companies for over 25 years, providing innovative debt solutions that help entrepreneurs and their investors grow their companies while minimising dilution.

For more information visit www.claret-capital.com

Claret Capital Partners Limited (company registered number 12516001) is authorised and regulated by the Financial Conduct Authority (FRN 993228).

SOURCE Neurent Medical

Share this article

Visible improvement observed in longstanding melasma following a tailored Collagen P.I.N.® + PRX8 treatment protocol

LOUISVILLE, Ky., Sept. 9, 2026 /PRNewswire/ -- Induction Therapies, innovators in aesthetics and advanced microneedling technology, and Collagen P.I.N.®, in partnership with renowned aesthetic physician Dr. Shino Bay Aguilera, announced new clinical findings evaluating a treatment protocol combining Collagen P.I.N.® microneedling with PRX8, a plant-derived exosome product, for the appearance of melasma in Fitzpatrick skin type V.

The evaluation followed a woman with Fitzpatrick skin type V and longstanding facial melasma who had previously used topical hydroquinone and tranexamic acid. She received four Collagen P.I.N. treatments over eight weeks, with TRUExosomes PRX8 Plant-Exo Stimulation Serum applied after each treatment and daily sunscreen use maintained throughout the protocol. Visible improvement in the appearance of melasma was observed throughout the treatment course and continued at the final two-week follow-up after the fourth treatment with no adverse reactions reported.

"What makes these findings particularly compelling is what they underscore about treating pigmentation concerns in skin of color: technique, customization and clinical judgment matter," said Dr. Shino Bay Aguilera. "The combination of Collagen P.I.N.® and PRX8 also gives us an opportunity to evaluate how these modalities may work together as part of a comprehensive treatment protocol, rather than viewing PRX8 simply as a topical product."

"We know that patients are looking for effective, evidence-informed options that take their skin type into account," said Angelia Inscoe, Founder of Induction Therapies® and Collagen P.I.N. "These findings are encouraging because they highlight the importance of thoughtful treatment protocols and appropriately performed microneedling, while contributing to the broader conversation around how we can continue advancing aesthetic care for diverse patients."

These findings advance the understanding of properly performed microneedling and combination treatment approaches across diverse skin types, reinforcing the importance of personalized protocols and clinician expertise in optimizing patient outcomes.

The full study can be found here. For more information, please visit inductiontherapies.com and collagenpin.com.

About Induction Therapies® | Collagen P.I.N.®

Induction Therapies is a clinically driven aesthetics company redefining how treatments, skincare, and outcomes work together. Founded by industry veteran and serial entrepreneur, Angelia Inscoe, the brand was built on a simple but often overlooked truth: meaningful results don't come from a single product or procedure — they come from a system.

At the center of this philosophy is the Collagen P.I.N.® microneedling device, the first of its kind to introduce an industry-leading 36-pin needle cartridge and precision depth up to 3.0mm, expanding what microneedling can achieve in both performance and versatility. Engineered to create more microchannels with greater control, it delivers enhanced collagen stimulation, deeper product absorption, and more consistent, high-performance outcomes.

SOURCE Collagen P.I.N.

Share this article

Six Cases Across Mitral, LAA, and PFA Workflows Completed with Zero Complications

LEXINGTON, S.C., Sept. 9, 2026 /PRNewswire/ -- ElectroWire Medical, developer of the FDA-cleared LightningWire™ Transseptal Puncture System, today announced the successful completion of its first clinical cases, performed at Spartanburg Medical Center in Spartanburg, South Carolina.

The procedures were performed by Dr. Nalin Srivastava, a structural interventional cardiologist, and Dr. David Rodak, a cardiac electrophysiologist, and included one mitral valve repair, one left atrial appendage occlusion, and four pulsed field ablations. The cases were performed using four different transseptal introducers and two different electrosurgical generators, demonstrating the LightningWire system's compatibility across a range of operator-preferred and already-available equipment. All procedures were completed successfully with no complications.

Dr. Srivastava performed first-in-human use of the LightningWire system, successfully delivering a 24-French steerable guide catheter into the left atrium for mitral valve repair. "I think you're onto something here," he said. "The mechanical and electrosurgical performance of the LightningWire, combined with ease of use with the operator having control of the RF on the table, makes this a very attractive option to streamline every transseptal procedure."

"Before clinical use, it's difficult to know if you've made something that will work well in the real world, and that people will actually want," said Dr. Robert Leonardi, Founder of ElectroWire Medical. "We're thrilled to see the LightningWire system work beautifully in a variety of transseptal procedures in the real world, and for physicians and laboratory staff to provide positive feedback." The LightningWire technology is positioned to bring value to all procedures in the rapidly growing transseptal access systems market, including catheter ablation of atrial fibrillation, left atrial appendage occlusion, and transcatheter mitral valve repair and replacement.

About LightningWire™

The LightningWire system combines a novel electrosurgical guidewire and activation cable to simplify transseptal puncture and delivery of cardiovascular devices. The LightningWire's proprietary insulation design optimizes mechanical properties and electrosurgical performance along the length of the wire. Despite its 0.032-inch labeled diameter, which facilitates broad compatibility with various transseptal devices, the LightningWire is stiffer than the market-leading 0.035-inch guidewire1 to support efficient transseptal delivery of therapy devices. Robust insulation allows transseptal puncture at low power settings. Further improving compatibility, the LightningWire's activation cable connects to separately cleared, pre-existing electrosurgical generators and puts control of radiofrequency energy in the operator's hands on the sterile field.

About ElectroWire Medical

ElectroWire Medical is a Lexington, South Carolina-based medical device technology startup focused on setting new standards for transseptal access and device delivery. Its flagship product, the LightningWire Transseptal Puncture System, is FDA-cleared and in limited market release. For more information, visit https://electrowiremedical.com/. For updates, follow ElectroWire Medical on LinkedIn and X.

Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. For indications and important safety information, visit https://www.electrowiremedical.com/isi.

1 Data on File at ElectroWire Medical

SOURCE ElectroWire Medical

Share this article

Detailed Phase 3 CANOPY-HCH-3 data in children living with hypochondroplasia also featured in a late-breaking oral presentation at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting

VOXZOGO demonstrated statistically significant improvements across multiple measures of growth, including annualized growth velocity, standing height, height Z-score and arm span

BioMarin recently submitted a supplemental New Drug Application (sNDA) to the FDA to support expanding treatment with VOXZOGO to include children with hypochondroplasia

SAN RAFAEL, Calif., Sept. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data from the Phase 3 CANOPY-HCH-3 study evaluating VOXZOGO® (vosoritide) in children with hypochondroplasia were published in New England Journal of Medicine (NEJM) Evidence and presented at the European Society for Paediatric Endocrinology (ESPE) 2026 Annual Meeting. The data included new results on the magnitude of benefit seen in children receiving VOXZOGO, including statistically significant improvements in annualized growth velocity (AGV), standing height, height Z-score and arm span after 52 weeks, with safety findings consistent with the established profile of VOXZOGO in achondroplasia.

The CANOPY-HCH-3 study showed that treatment with VOXZOGO led to a statistically significant improvement in AGV compared with placebo after 52 weeks, meeting the study's primary endpoint (least squares [LS] mean difference of 2.33 cm/year; p0.0001). Children treated with VOXZOGO also showed significant improvements in standing height (LS mean difference of 2.35 cm; p0.0001), height Z-score (LS mean difference of 0.39 standard deviation score; p0.0001), and arm span (LS mean difference of 1.03 cm; p=0.0082) compared with placebo. Children who received VOXZOGO also demonstrated numerical improvements in quality of life, and follow-up will continue to assess the impact of treatment over a longer term. The overall safety profile was consistent with previous studies of VOXZOGO, with most adverse events reported as mild and no treatment-related serious adverse events identified.

"These results presented in detail for the first time provide a comprehensive picture of the impact of VOXZOGO across multiple measures of growth in children with hypochondroplasia," said Greg Friberg, M.D., Executive Vice President and Chief Research & Development Officer at BioMarin. "Based on this compelling body of evidence, we have submitted these data to the FDA with the goal of securing approval for the first medicine for children with hypochondroplasia."

"Hypochondroplasia can affect a child's growth, physical function and everyday life, with families often navigating unique challenges as they support their children's development," said Andrew Dauber, M.D., lead study investigator and Chief of Endocrinology at Children's National in Washington, D.C. "The changes we observed in annualized growth velocity and arm span provide encouraging evidence of how children with hypochondroplasia responded to treatment throughout the study. These findings deepen our understanding of the condition while reinforcing VOXZOGO's potential as the first targeted medicine developed specifically for children with hypochondroplasia."

BioMarin recently submitted its supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of VOXZOGO for the treatment of hypochondroplasia and are on track with the submissions to the European Medicines Agency (EMA) and other regional health authorities. If approved, VOXZOGO would be the first targeted therapy for the treatment of hypochondroplasia, with a potential 2027 launch.

Below are key BioMarin presentations across both achondroplasia and hypochondroplasia at ESPE, with all times listed in Central European Summer Time:

Vosoritide Increases Growth Velocity in Children With Hypochondroplasia: Phase 3 Trial Results

Oral Presentation #LBA 1067

Wednesday, Sept. 9, 10:48 – 10:56 a.m.

Vosoritide Safety and Effectiveness in Young Children With Achondroplasia Aged ≤3 Years and With up to 36 Months of Follow-Up from the Japanese Post-Marketing Safety Surveillance Study (111-604)

Oral Presentation #FC3.4

Tuesday, Sept. 8, 3:30 – 3:40 p.m.

About Hypochondroplasia

Hypochondroplasia is a rare, genetic skeletal dysplasia characterized by impaired bone growth, leading to disproportionate short stature and skeletal differences that can affect the long bones, spine and other parts of the skeleton and may impact physical functioning and overall quality of life. The condition presents with a broad and variable clinical spectrum and may include otolaryngologic (related to the ears, nose and throat) and neurological complications and is often diagnosed in toddlerhood or early school age based on clinical and radiological findings. BioMarin estimates that roughly 14,000 children with hypochondroplasia within the company's global footprint may be eligible for treatment with VOXZOGO.

There are currently no medicines approved by the U.S. Food and Drug Administration or the European Medicines Agency for the treatment of hypochondroplasia.

For more information about our clinical trials in hypochondroplasia, achondroplasia and other skeletal conditions, please visit clinicaltrials.biomarin.com.

About VOXZOGO

In children with achondroplasia, endochondral bone growth, an essential process by which bone tissue is created, is negatively regulated due to a gain of function mutation in FGFR3. VOXZOGO, a C-type natriuretic peptide (CNP) analog, acts as a positive regulator of the signaling pathway downstream of FGFR3 to promote endochondral bone growth.

VOXZOGO is the only approved medicine to support the growth of children with achondroplasia starting from birth, with international consensus guidelines recommending initiation of VOXZOGO as early as possible. First approved in 2021, VOXZOGO has helped more than 5,000 infants and children in more than 50 countries. Through our ongoing studies, BioMarin continues to evaluate VOXZOGO on key clinical endpoints relevant for achondroplasia patients, such as arm span, tibial bowing (leg bowing), body proportionality, spinal morphology (including spinal stenosis) and quality of life measures.

VOXZOGO is approved in the U.S., Japan and Australia to increase linear growth in children of all ages with achondroplasia with open epiphyses, and VOXZOGO is indicated in the EU for the treatment of achondroplasia in children 4 months of age and older whose epiphyses are not closed, as confirmed by appropriate genetic testing. In the U.S., this indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s). An sNDA with long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth such as body proportionality and arm span is under review with an FDA Prescription Drug User Fee Act (PDUFA) target action date of Feb. 28, 2027.

The use of VOXZOGO to treat hypochondroplasia has not yet been approved by any regulatory agency.

VOXZOGO U.S. Important Safety Information

What is VOXZOGO used for?

- VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).

- VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

What is the most important safety information about VOXZOGO?

- VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

What are the most common side effects of VOXZOGO?

- The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomachache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

How is VOXZOGO taken?

- VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.

- Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.

- The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.

- Your healthcare provider will monitor the patient's growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

What should you tell the doctor before or during taking VOXZOGO?

The Great Greek Mediterranean Grill Announces Partnership with PepsiCo and Launches New Signature Lemonades & Refreshers

7-Year national beverage partnership enhances the guest experience with expanded beverage choices while delivering added value and support across The Great Greek franchise system

WEST PALM BEACH, Fla., Sept. 9, 2026 /PRNewswire/ -- Guests can now enjoy their favorite PepsiCo beverages while enjoying a meal at The Great Greek Mediterranean Grill®. The two companies announced their partnership, making PepsiCo the official provider of soft drinks for the fast-casual restaurant brand.

Rolling out nationwide through 2026, the partnership brings The Great Greek Mediterranean Grill a best-in-class beverage platform designed to enhance its fresh, better-for-you Mediterranean menu. The collaboration introduces a delicious and refreshing lineup of PepsiCo beverages — from the flagship Pepsi® brand to iconic products such as Aquafina®, Pure Leaf®, and Celsius®, as well as custom lemonades and refreshers— all crafted to deliver premium beverage pairings that elevate the dining experience.

"As an emerging brand, having the right partners makes all the difference. That's why we're proud to partner with PepsiCo, a legendary company that's recognized and admired around the world for its brands," said Bob Andersen, President of The Great Greek Mediterranean Grill. "PepsiCo is more than a supplier to The Great Greek; they're an extension of our team. Beyond the benefits for our guests, this collaboration elevates our beverage program in ways that directly support our franchise community — from stronger marketing opportunities to enhanced systemwide support. They've consistently brought the collaboration, resources, and commitment we need to compete, positioning our franchise owners and brand for long-term success."

Guests at The Great Greek Mediterranean Grill can enjoy a broad portfolio of PepsiCo beverages across fountain, bottle and can offerings, providing the perfect complement to any meal and satisfying a variety of refreshment occasions. The selection includes iconic soft drinks like Pepsi® Zero Sugar and Mountain Dew®, sparkling water, teas, hydration options like Gatorade®, energy beverages, and delicious lemonade refreshers in four flavors including Homestyle Lemonade, Mango Lemonade, Orange Passionfruit Refresher, and Strawberry Watermelon Refresher. The beverage lineup offers guests a range of delicious choices for meal pairings. Beverage and flavor selections may vary by location.

"The Great Greek Mediterranean Grill has built an impressive brand by delivering fresh, flavorful food and a guest experience that resonates with consumers," said Quinitta Shumpert, PepsiCo Regional Vice President. "At PepsiCo, our role is to help restaurant operators build on that success through a combination of iconic beverage brands, innovation, marketing support and foodservice expertise. We're proud to partner with The Great Greek to enhance the guest experience while supporting the brand's continued growth."

PepsiCo offers refreshing beverage options that pair perfectly with the bold flavor profiles of The Great Greek Mediterranean Grill, which embody the restaurant's mission to Live Great, Eat Greek. Each dish is created using only the highest-quality ingredients and served in an elevated fast-casual atmosphere to create a dining experience that exceeds expectations. Together, they make a meal that satisfies all levels.

To find The Great Greek Mediterranean Grill nearest to you or order online, visit www.thegreatgreekgrill.com/locations. Follow The Great Greek Mediterranean Grill on Instagram at @greatgreekgrill.

About The Great Greek Mediterranean Grill

The award-winning Great Greek Mediterranean Grill® is a leading franchise within the Greek, Mediterranean, and Middle Eastern fast-casual restaurant industry, serving a vibrant menu inspired by the fresh, flavorful ingredients of the Mediterranean diet. Each dish is prepared fresh, in-house to deliver bold flavor in every bite. Co-founded by two culinary trained, third-generation restauranteurs, Nick A. Della Penna and Trent Jones, The Great Greek Mediterranean Grill is an affiliated brand of United Franchise Group™, a globally recognized leader in franchising. For more information about The Great Greek Mediterranean Grill locations, menu and catering visit www.thegreatgreekgrill.com and for franchise information, visit www.thegreatgreekfranchise.com.

About PepsiCo

PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated nearly $92 billion in net revenue in 2024, driven by a complementary beverage and convenient foods portfolio that includes Lay's, Doritos, Cheetos, Gatorade, Pepsi-Cola, Mountain Dew, Quaker, and SodaStream. PepsiCo's product portfolio includes a wide range of enjoyable foods and drinks, including many iconic brands that generate more than $1 billion each in estimated annual retail sales.

Guiding PepsiCo is our vision to Be the Global Leader in Beverages and Convenient Foods by Winning with pep+ (PepsiCo Positive). pep+ is our strategic end-to-end transformation that places sustainability at the center of our business strategy, seeking to drive growth and build a stronger, more resilient future for PepsiCo and the communities where we operate. For more information, visit www.pepsico.com, and follow on X (Twitter), Instagram, Facebook, and LinkedIn @PepsiCo.

Media Contact: Caitlin Willard, TilsonPR, [email protected]

SOURCE The Great Greek Mediterranean Grill

Share this article

Sysmac Studio projects on Omron NJ and NX-series controllers can now be automatically backed up, version-controlled, and restored through Copia's platform.

CHICAGO and NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Copia Automation today announced that Copia's OT code management and recovery platform now supports Omron Sysmac Studio, extending automated backup, version control, and rapid recovery to manufacturers running Omron NJ and NX-series devices. With this integration, Copia customers can bring the same modern code management and recovery discipline to Sysmac Studio-based operations that Copia already provides for Rockwell, Siemens, and other vendor environments.

When operations go down, recovery time is what determines the business impact. Yet the code running programmable logic controllers (PLCs) and other automation devices may be rarely versioned, backed up regularly, or tested for recoverability. Industrial backups can often live on an engineer's laptop, on a USB drive in a drawer, or worse, nowhere at all. When something goes wrong, whether a cyber incident, a bad code push, or a hardware failure, recovery may depend on who's in the building and what they remember.

Copia DeviceLink™ automatically backs up Sysmac Studio projects, so OT teams always have a verified last known version to restore to. Copia also detects unauthorized or accidental changes at the device level and gives engineers a full change history with visual diffs to validate edits and roll back in minutes. Sysmac Studio projects sit alongside code from every other controller in the plant, in a single, centralized system of record. Because Copia was built for OT, it slots into segmented, security-sensitive networks without opening new inbound ports.

"Copia has brought the science of reliable version control to OT sites across the Americas. It is great to see a user-first organization continue to invest in software that protects the code running critical operations," said Thomas Kuckhoff, Product Manager Supervisor at Omron Automation Americas.

"The code running the physical world deserves the same rigor that software has had for two decades, and that includes the ability to recover quickly when something goes wrong," said Matt Lee, Co-Founder and VP of Business Development at Copia Automation. "The recovery gap in OT is real. When something breaks on the line, most teams are still hunting for the last known verified copy on someone's laptop while every minute of downtime adds up. Every plant we walk into runs a mix of controllers, and Omron is a major part of that reality. Extending Copia to Sysmac Studio means our customers no longer have to choose between the controller that best fits the application and the resilience they need to keep it running."

With the new integration, Copia customers can:

- Schedule automated backups of Sysmac Studio projects across devices, eliminating manual, error-prone backups.

- Receive real-time alerts on code changes, allowing engineering and security teams to investigate unexpected or unauthorized edits before they cause downtime.

- Compare versions visually, validate legitimate changes, and merge updates through Copia's Git-based Source Control.

- Recover the last known verified Sysmac Studio project quickly to minimize disruption and hit recovery time objectives with confidence.

- Manage Omron devices alongside other PLC brands in a unified view, without switching tools.

To learn more about this new integration, request a demo at copia.io/request-a-demo.

About Omron Automation

Omron Automation is an industrial automation partner that creates, sells, and services fully integrated automation solutions that include sensing, control, safety, vision, motion, and more. Established in 1933, Omron's 30,000 employees help businesses solve problems with creativity in more than 110 countries.

About Copia Automation

Copia Automation provides visibility, traceability, and control across the full automation lifecycle, helping industrial teams maximize uptime, strengthen governance, and build resilient operations. From OT teams on the plant floor to the executives accountable for cyber resilience and compliance, Copia gives organizations a single platform to manage, secure, and recover the industrial code that runs the physical economy. Learn more at copia.io.

SOURCE Copia Automation

Share this article